SCYNEXIS, Inc. (SCYX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. SCYNEXIS, Inc. is a biotechnology company developing proprietary triterpenoid antifungal compounds ("fungerps"). Its approved product, BREXAFEMME (ibrexafungerp), is licensed to GlaxoSmithKline (GSK). The company is currently advancing its second-generation candidate, SCY-247, for invasive candidiasis and other fungal infections. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0.33 million | $0.66 million | $1.96 million | $2.77 million |
| Net Loss | $(8.59) million | $(2.81) million | $(20.87) million | $(16.86) million |
| Operating Expenses | $8.74 million | $10.98 million | $28.55 million | $31.83 million |
| Cash & Investments | $37.93 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $397.40 million (as of Sept 30, 2025) | |||
| Debt | $0 (Convertible debt repaid in March 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 49% in Q3 and 29% YTD compared to the prior year, driven by the timing of license agreement revenue recognition from the GSK agreement.
- Increased Net Loss: Net loss widened significantly in Q3 2025 ($8.6M) compared to Q3 2024 ($2.8M). This was primarily due to a $7.4M swing in warrant liability fair value adjustments (a $0.6M loss in 2025 vs. a $6.8M gain in 2024).
- Expense Reduction: Operating expenses decreased 20% YTD, largely due to reduced Chemistry, Manufacturing, and Controls (CMC) costs and the completion of prior clinical studies (FURI and CARES).
- Debt Repayment: The company fully repaid its $14.0 million March 2019 convertible notes in March 2025, eliminating interest expense and amortization of debt issuance costs for the remainder of the year.
- Warrant Liability: The fair value of warrant liabilities decreased from $8.0 million at year-end 2024 to $3.5 million at September 30, 2025, resulting in a non-cash gain of $4.5 million YTD.
Outlook, Risks, and Unusual Items
- GSK MARIO Study Resolution: In October 2025 (subsequent event), SCYNEXIS and GSK agreed to terminate the MARIO study. SCYNEXIS will receive one-time payments totaling $24.8 million. No additional milestones for this specific study will be paid.
- SCY-247 Progress: Phase 1 oral studies for SCY-247 were completed with positive safety and pharmacokinetic results. An IV Phase 1 study is planned for Q1 2026, with a Phase 2 proof-of-concept study anticipated in 2026.
- Liquidity: Management believes current capital resources ($37.9 million) are sufficient to fund operations for at least 12 months. However, the company expects to incur significant losses and will require additional capital for future development.
- Nasdaq Compliance: The company received a notification in June 2025 regarding non-compliance with the $1.00 minimum bid price rule. It has until December 17, 2025, to regain compliance.
- Legal Proceedings: A securities class action filed in 2023 was dismissed with prejudice in August 2025. A related shareholder derivative action was dismissed without prejudice in October 2025.
Investor Verification Checklist
- Collection of GSK Payment: Verify the receipt and timing of the $24.8 million settlement payment from GSK regarding the MARIO study termination.
- Stock Price Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by the December 17, 2025, deadline to avoid delisting risks.
- Capital Raise Needs: Assess the timeline for potential equity offerings or debt financings given the $397.4 million accumulated deficit and ongoing R&D burn rate.
- SCY-247 Clinical Data: Review upcoming data releases from the Phase 1 oral study and the initiation of the IV Phase 1 study in early 2026.
- Warrant Liability Volatility: Monitor the fair value adjustments of warrant liabilities, which significantly impact reported net loss but are non-cash items.